Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

±¸°­ÆíÆòż±¿¡ ´ëÇÑ sulfasalzineÀÇ ±¹¼ÒÀû¿ë

A New Treatment Modality Using Topical Sulfasalazine for Oral Lichen Planus

´ëÇѱ¸°­³»°úÇÐȸÁö 2012³â 37±Ç 3È£ p.155 ~ 159
Á¤¼ö¹Î, ¹Ú¼öÇö, ¿Á¼ö¹Î, ÇãÁØ¿µ, °í¸í¿¬, ¾È¿ë¿ì,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤¼ö¹Î ( Jeong Su-Min ) - ºÎ»ê´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç
¹Ú¼öÇö ( Park Su-Hyeon ) - ºÎ»ê´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç
¿Á¼ö¹Î ( Ok Soo-Min ) - ºÎ»ê´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç
ÇãÁØ¿µ ( Heo Jun-Young ) - ºÎ»ê´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç
°í¸í¿¬ ( Ko Myung-Yun ) - ºÎ»ê´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç
¾È¿ë¿ì ( Ahn Yong-Woo ) - ºÎ»ê´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç

Abstract

±¸°­ÆíÆòż±Àº ¸é¿ª¸Å°³¼º ¹ÝÀÀÀ¸·Î À¯¹ßµÇ´Â ¸¸¼º¿°ÁõÁúȯÀ¸·Î Á¤ÀÇÇÒ ¼ö ÀÖÀ¸¸ç ±× Á¤È®ÇÑ ¿øÀÎÀº ¾ÆÁ÷ ¹àÇôÁöÁö ¾ÊÀº »óÅÂÀÌ´Ù. ÀϹÝÀûÀ¸·Î ½ºÅ×·ÎÀ̵带 ÀÌ¿ëÇÑ ±¹¼ÒÀû ¶Ç´Â Àü½ÅÀû Ä¡·á¸¦ ½ÃÇàÇÏ°í ÀÖÀ¸³ª ½ºÅ×·ÎÀ̵å Ä¡·á¿¡ ¹ÝÀÀÀÌ ¾ø´Â ȯÀÚÀÇ °æ¿ì¿¡´Â Ä¡·á°¡ Èûµé´Ù. SulfasalzineÀº ¿°Áõ¼º ÀåÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ ¾à¹°·Î ¼±Åõǰí ÀÖ°í ·ù¸¶Æ¼½º¼º °üÀý¿°¿¡¼­µµ Ä¡·áÁ¦·Î »ç¿ëÇÏ°í ÀÖ´Ù. ¿°Áõ¼º ÀåÁúȯ°ú ±¸°­ÆíÆòż±¿¡¼­ ¹ßº´±âÀüÀ» »ìÆ캸¸é °øÅëÀûÀÎ ºÎºÐÀÌ ¸¹ÀÌ ¹ß°ßµÈ´Ù. Àü½ÅÀûÀ¸·Î Åõ¿©½Ã ³ªÅ¸³ª´Â ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ°í Á¢±ÙÀÇ ÆíÀ̼ºÀ» À§ÇÏ¿© SulfasalzineÀ» ±¸°­ÆíÆòż±¿¡ ±¹¼Ò µµÆ÷ÀÇ ÇüÅ·Π½ÃµµÇÏ¿´À¸¸ç, º» ¿¬±¸¿¡¼­´Â ¼º°øÀûÀ¸·Î Ä¡·áÇÑ 2 Ä¡Çè·Ê¸¦ ¼Ò°³ÇÏ¿´´Ù. ù¹ø° Áõ·Ê¿¡¼­´Â 8ÁÖ°£ÀÇ µµÆ÷(30mg/5ml, ÇÏ·ç3¹ø) ÈÄ Áõ»óÀÌ ¿ÏÈ­µÇ¾úÀ¸¸ç, µÎ¹ø° Áõ·Ê¿¡¼­´Â 15ÁÖ°£ÀÇ µµÆ÷ ÈÄ Áõ»óÀÌ ¿ÏÈ­µÇ¾ú´Ù. µÎ Áõ·Ê ¸ðµÎ ½ºÅ×·ÎÀ̵忡 Ä¡·á¹ÝÀÀÀÌ ¾ø¾ú´ø ȯÀÚ¿´À¸¸ç sulfasalazine µµÆ÷ ÈÄ ÇöÀç±îÁö Áõ»óÀÌ ¿ÏÈ­µÈ »óÅ·ΠÁö³»°í ÀÖ´Ù. µû¶ó¼­ SulfasalazineÀº ±¸°­ÆíÆòż±È¯ÀÚ¿¡¼­ Ä¡·á¾à¹°·Î ¼±ÅÃµÉ ¼ö ÀÖ´Ù´Â °á·ÐÀ» ¾ò¾ú´Ù.

Background Oral lichen planus (OLP) is a chronic inflammatory disease characterized by cell-mediated immune responses, but the exact cause is unknown. Sulfasalazine has shown efficacy in the treatment of cutaneous lichen planus. Objective Our purpose was to assess the usefulness of sulfasalazine in treatment of OLP resistant to corticosteroid therapy. This study provides a new option for controlling OLP symptoms. Methods Two patients with the symptomatic reticular form of OLP were treated with 30 mg/5 ml of topical sulfasalazine for 8 to 15 weeks and were evaluated for symptom severity using a numerical analog scale during each week of treatment. The lesion size was measured using a 2 grid. Results After 2 weeks of application, both patients reported improvements in their symptoms and lesions. Most of the lesions disappeared after 8 weeks of treatment without any side effects. Conclusion Topical sulfasalazine can be a successful treatment option for patients with oral lichen planus resistant to steroid therapy.

Å°¿öµå

±¸°­ÆíÆòż±; ±¹¼ÒÀû¿ë; ¼³ÆÄ»ì¶óÁø
Oral lichen planus; Resistant to corticosteroid; Sulfasalazine; Topical application

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI